InspireMD, Inc. Files 8-K on Financials

Ticker: NSPR · Form: 8-K · Filed: Nov 4, 2025 · CIK: 1433607

Inspiremd, INC. 8-K Filing Summary
FieldDetail
CompanyInspiremd, INC. (NSPR)
Form Type8-K
Filed DateNov 4, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, operations, disclosure

TL;DR

InspireMD dropped an 8-K on Nov 4th covering financials & operations. Check it for the latest.

AI Summary

InspireMD, Inc. filed an 8-K on November 4, 2025, reporting on its financial condition and operations. The filing also includes disclosures under Regulation FD and presents financial statements and exhibits. The company is incorporated in Delaware and headquartered in Miami, Florida.

Why It Matters

This 8-K filing provides crucial updates on InspireMD's financial health and operational status, which are important for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for InspireMD, Inc.?

The primary purpose is to report on the Results of Operations and Financial Condition, provide Regulation FD Disclosures, and present Financial Statements and Exhibits.

When was this 8-K report filed?

The report was filed on November 4, 2025.

In which state is InspireMD, Inc. incorporated?

InspireMD, Inc. is incorporated in Delaware.

What is the principal executive office address for InspireMD, Inc.?

The principal executive offices are located at 6303 Waterford District Drive, Suite 215, Miami, Florida 33126.

What was InspireMD, Inc.'s former company name?

InspireMD, Inc.'s former company name was Saguaro Resources, Inc.

Filing Stats: 684 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2025-11-04 16:06:48

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On November 4, 2025, InspireMD, Inc. (the "Company") issued a press release announcing its financial and operating results and recent highlights for the three and nine months ended September 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 4, 2025, the Company made available an updated investor presentation. A copy of the presentation is attached hereto as Exhibit 99.2 and incorporated by reference in this Item 7.01. A copy of the presentation is also available on the Company's website https://www.inspiremd.com/en/investors/. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 7.01 shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release, dated November 4, 2025 (furnished herewith pursuant to Item 2.02) 99.2 Investor Presentation November 2025 (furnished herewith pursuant to Item 7.01) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INSPIREMD, INC. Date: November 4, 2025 By: /s/ Michael Lawless Name: Michael Lawless Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing